Brigatinib
Back to searchMolecule Structure
Scientific Name
Brigatinib
Description of the Drug
Brigatinib is an anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12267
http://www.drugbank.ca/drugs/DB12267
Brand Name(s)
Alunbrig
Company Owner(s)
Takeda Pharmaceuticals Usa Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Epidermal growth factor receptor erbB1 | SINGLE PROTEIN | INHIBITOR | CHEMBL203 |
| ALK tyrosine kinase receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL4247 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL11916361 | |
| PharmGKB | PA166163482 | |
| Human Metabolome Database | HMDB0249380 | |
| DrugBank | DB12267 | |
| PubChem | 68165256 | |
| Nikkaji | J3.535.964H | |
| PDBe | 6GY | |
| BindingDB | 50185140 | |
| DrugCentral | 5233 | |
| Brenda | 255718 | |
| ChemicalBook | CB43041390 | |
| rxnorm | BRIGATINIB | ALUNBRIG |
| ZINC | ZINC000148723177 |
